Thyrocare Technologies Limited's 26th AGM: All resolutions passed, including dividend declaration.
Thyrocare Technologies Limited's 26th AGM on June 30, 2026, saw the approval of FY26 financial statements and a total dividend of ₹14.00 per equity share (₹7.00 final, ₹7.00 interim). Key approvals included re-appointing Mr. Alok Kumar Jagnani, appointing new auditors, and confirming directors Mr. Gaurav Verma and Mr. Uday Patel Kadam.
The AGM outcome is significant as it covers financial approvals, dividend distribution, and board appointments, impacting shareholder confidence and corporate direction.
The announcement details the successful conclusion of the AGM with all resolutions passed, including the declaration of dividends and key appointments, indicating smooth corporate governance.
Thyrocare Technologies Limited held its 26th Annual General Meeting (AGM) on Tuesday, June 30, 2026, at its Corporate Office in Navi Mumbai. The meeting, which commenced at 11:00 A.M. and concluded at 12:30 P.M., was attended by 66 shareholders, representing 61.10% of the total paid-up equity share capital.
During the AGM, shareholders approved the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. A final dividend of ₹7.00 per equity share, along with a confirmed interim dividend of ₹7.00 per equity share (pre-bonus adjustment, equivalent to ₹2.33 post-bonus adjustment), was declared for the financial year ended March 31, 2026.
Key appointments and re-appointments were also approved: Mr. Alok Kumar Jagnani was re-appointed as a director retiring by rotation. M/s. Price Waterhouse Chartered Accountants LLP were appointed as the Statutory Auditors for a five-year term. The remuneration of M/s. Jitender Navneet & Co., the Cost Auditors, was ratified. Additionally, Mr. Gaurav Verma and Mr. Uday Patel Kadam were appointed as Non-Executive and Non-Independent Directors, effective May 08, 2026. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director, and Chief Executive Officer, effective May 04, 2027. Approval was also granted for entering into Material Related Party Transactions with Docon Technologies Private Limited and for an amendment to the Memorandum of Association (MOA) of the Company.
All resolutions, including ordinary and special businesses, were passed with the requisite majority. The detailed voting results and a summary of proceedings have been submitted to the National Stock Exchange of India Limited and BSE Limited, and are also available on the company's website and the e-voting website of CDSL.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.